Retrospective cohort study of correlation between immune check point molecular inhibitor and response factor, side effect, and post treatment
Not Applicable
- Conditions
- Patients with non-resectable advanced or recurrent NSCLC receiving treatment with nivolumab
- Registration Number
- JPRN-UMIN000025908
- Lead Sponsor
- Osaka Medical Center for Cancer and Cardiovascular
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up continuing
- Sex
- All
- Target Recruitment
- 200
Inclusion Criteria
Not provided
Exclusion Criteria
Patients who have previously received nivolumab in a clinical trial will be excluded
Study & Design
- Study Type
- Others,meta-analysis etc
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method